<blockquote id="caagf"></blockquote>
返回
公司介紹
董事會
管理團隊
合作伙伴
企業榮譽
專利布局
納基奧侖賽
認證醫療機構名單
創新支付
研發管線
學術發表
公司新聞
產品新聞
媒體報道
企業文化
招賢納士
Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma:Long-Term Results of a Pilot Prospective Clinical Study
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
CNCT19 for Treatment of Patients with Relapsed Refractory B-Cell AcuteLymphoblastic Leukemia (r/r B-cell ALL) in Children and Adults
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
查看更多 +
010-65960020
